[시장보고서]항암제 시장 : 세계 산업 규모, 점유율, 동향, 기회, 예측 - 적응증별, 약물별, 투여 경로별, 최종사용자별, 지역별, 경쟁별(2020-2030년)

항암제 시장 : 세계 산업 규모, 점유율, 동향, 기회, 예측 - 적응증별, 약물별, 투여 경로별, 최종사용자별, 지역별, 경쟁별(2020-2030년)

Anticancer Drug Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Indication, By Drug, By Route of Administration, By End User, By Region and Competition, 2020-2030F

상품코드 : 1878881

리서치사 : TechSci Research

발행일 : 2025년 11월

페이지 정보 : 영문 185 Pages

라이선스 & 가격 (부가세 별도)

US $ 4,500

￦ 6,681,000

Unprintable PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 불가능하며, 텍스트의 Copy&Paste도 불가능합니다.

US $ 5,500

￦ 8,165,000

PDF and Excel (Multi-User License)

PDF 및 Excel 보고서를 기업의 팀이나 기관에서 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 및 Excel 이용 범위와 동일합니다.

US $ 8,000

￦ 11,877,000

PDF and Excel (Custom Research License)

PDF 및 Excel 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 및 Excel 이용 범위와 동일합니다. 80시간의 애널리스트 타임이 포함되어 있고 Copy & Paste 가능한 PPT 버전도 제공됩니다. 짧은 Bespoke 리서치 프로젝트 수행에 맞는 라이선스입니다.

ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.

한글목차

샘플 요청 목록에 추가

세계의 항암제 시장은 2024년에 1,799억 3,000만 달러로 평가되었으며, 2030년까지 CAGR 5.25%로 성장하여 2,445억 9,000만 달러에 달할 것으로 예측됩니다.

항암제는 악성 세포를 억제하거나 파괴하기 위해 특별히 제조된 의약품으로, 다양한 암 치료 전략의 기반이 됩니다. 시장 확대는 주로 전 세계적으로 증가하는 암 발병률, 종양성 질환에 취약한 고령화 인구의 증가, 새로운 치료법의 돌파구를 여는 의료 연구의 지속적인 발전에 의해 주도되고 있습니다.

시장 개요
예측 기간	2026-2030년
시장 규모 : 2024년	1,799억 3,000만 달러
시장 규모 : 2030년	2,445억 9,000만 달러
CAGR : 2025-2030년	5.25%
가장 빠르게 성장하는 부문	유방암
최대 시장	북미

주요 시장 촉진요인

주요 시장 과제

주요 시장 동향

시장 규모 및 예측
- 금액별
시장 점유율과 예측
- 적응증별(유방암, 혈액암, 전립선암, 소화기암, 부인과암, 폐암, 기타)
- 약물별(세포독성 약물, 호르몬요법, 표적요법, 기타)
- 투여 경로별(경구, 비경구, 기타)
- 최종사용자별(병원·진료소, 외래 진료 센터, 기타)
- 지역별
- 기업별(2024)
시장 맵

제6장 북미의 항암제 시장 전망

시장 규모 및 예측
시장 점유율과 예측
북미 : 국가별 분석
- 미국
- 캐나다
- 멕시코

제7장 유럽의 항암제 시장 전망

시장 규모 및 예측
시장 점유율과 예측
유럽 : 국가별 분석
- 독일
- 프랑스
- 영국
- 이탈리아
- 스페인

제8장 아시아태평양의 항암제 시장 전망

시장 규모 및 예측
시장 점유율과 예측
아시아태평양 : 국가별 분석
- 중국
- 인도
- 일본
- 한국
- 호주

제9장 중동 및 아프리카의 항암제 시장 전망

시장 규모 및 예측
시장 점유율과 예측
중동 및 아프리카 : 국가별 분석
- 사우디아라비아
- 아랍에미리트
- 남아프리카공화국

제10장 남미의 항암제 시장 전망

시장 규모 및 예측
시장 점유율과 예측
남미 : 국가별 분석
- 브라질
- 콜롬비아
- 아르헨티나

제11장 시장 역학

성장 촉진요인
과제

제12장 시장 동향과 발전

인수합병
제품 출시
최근 동향

제13장 세계의 항암제 시장 : SWOT 분석

제14장 Porter's Five Forces 분석

업계내 경쟁
신규 참여의 가능성
공급업체의 능력
고객의 능력
대체품의 위협

제15장 경쟁 구도

F. Hoffmann-La Roche Ltd.
Genentech, Inc.
Novartis AG
Pfizer Inc.
Bristol-Myers Squibb Company
GlaxoSmithKline plc.
Eli Lilly and Company(India) Pvt. Ltd.
AstraZeneca plc
Sanofi S.A.
Bayer AG

제16장 전략적 제안

제17장 조사 회사 소개 및 면책사항

KSM

영문 목차

영문목차

The Global Anticancer Drug Market, valued at USD 179.93 Billion in 2024, is projected to experience a CAGR of 5.25% to reach USD 244.59 Billion by 2030. Anticancer drugs represent pharmaceutical agents specifically formulated to inhibit or destroy malignant cells, serving as the cornerstone for various cancer treatment strategies. The market's expansion is primarily driven by the escalating global incidence of cancer, an expanding aging population predisposed to oncological diseases, and continuous advancements in medical research that foster novel therapeutic breakthroughs.

Market Overview
Forecast Period	2026-2030
Market Size 2024	USD 179.93 Billion
Market Size 2030	USD 244.59 Billion
CAGR 2025-2030	5.25%
Fastest Growing Segment	Breast Cancer
Largest Market	North America

Key Market Drivers

The increasing global cancer incidence substantially propels the anticancer drug market. A growing patient population naturally leads to a higher demand for diagnostic tools and subsequent therapeutic interventions, from chemotherapy to advanced targeted therapies. This demographic shift intensifies the need for a continuous supply of effective pharmaceuticals, driving companies to expand their portfolios. According to the International Agency for Research on Cancer, in 2022, there were an estimated 20 million new cancer cases worldwide, indicating a vast and expanding patient pool requiring treatment. The persistent rise in various cancer types underscores the demand for innovative drug solutions.

Key Market Challenges

A significant challenge impeding the growth of the global anticancer drug market is the considerable cost associated with the development and provision of advanced therapies. These high costs directly restrict patient access and affordability, particularly within emerging economies. This limitation reduces the eligible patient population for novel treatments, thereby hampering market penetration and overall sales volumes globally.

Key Market Trends

The integration of artificial intelligence (AI) in oncology is profoundly reshaping drug discovery and development processes. AI algorithms can analyze vast datasets, identify novel drug targets, and predict compound efficacy with increased speed and accuracy compared to traditional methods. This technological advancement significantly reduces the time and cost associated with bringing new anticancer drugs to market, fostering a more efficient and productive pipeline. According to Silicon Valley Bank, biotech AI attracted $5.6 billion in 2024, constituting nearly 30% of healthcare startup funding, reflecting a substantial increase driven by significant investment deals. This influx of capital underscores the industry's confidence in AI's transformative potential. For example, Insilico Medicine announced in June 2023 that its small molecule inhibitor drug candidate, INS018_055, an entirely AI-discovered and AI-designed drug, entered a phase 2 clinical trial for idiopathic pulmonary fibrosis, demonstrating the tangible progress of AI in therapeutic advancement.

Key Market Players

F. Hoffmann-La Roche Ltd.
Genentech, Inc.
Novartis AG
Pfizer Inc.
Bristol-Myers Squibb Company
GlaxoSmithKline plc.
Eli Lilly and Company (India) Pvt. Ltd.
AstraZeneca plc
Sanofi S.A.
Bayer AG

Report Scope:

In this report, the Global Anticancer Drug Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Anticancer Drug Market, By Indication:

Breast Cancer
Blood Cancer
Prostate Cancer
Gastrointestinal Cancer
Gynaecologic Cancer
Lung Cancer
Others

Anticancer Drug Market, By Drug:

Cytotoxics
Hormonal Therapy
Targeted Therapy
Others

Anticancer Drug Market, By Route of Administration:

Oral
Parenteral
Others

Anticancer Drug Market, By End User:

Hospitals & Clinics
Ambulatory Care Centers
Others

Anticancer Drug Market, By Region:

North America
- United States
- Canada
- Mexico
Europe
- France
- United Kingdom
- Italy
- Germany
- Spain
Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
South America
- Brazil
- Argentina
- Colombia
Middle East & Africa
- South Africa
- Saudi Arabia
- UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Global Anticancer Drug Market.

Available Customizations:

Global Anticancer Drug Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

1. Product Overview

1.1. Market Definition
1.2. Scope of the Market
- 1.2.1. Markets Covered
- 1.2.2. Years Considered for Study
- 1.2.3. Key Market Segmentations

2. Research Methodology

2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations

3. Executive Summary

3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Anticancer Drug Market Outlook

5.1. Market Size & Forecast
- 5.1.1. By Value
5.2. Market Share & Forecast
- 5.2.1. By Indication (Breast Cancer, Blood Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynaecologic Cancer, Lung Cancer, Others)
- 5.2.2. By Drug (Cytotoxics, Hormonal Therapy, Targeted Therapy, Others)
- 5.2.3. By Route of Administration (Oral, Parenteral, Others)
- 5.2.4. By End User (Hospitals & Clinics, Ambulatory Care Centers, Others)
- 5.2.5. By Region
- 5.2.6. By Company (2024)
5.3. Market Map

6. North America Anticancer Drug Market Outlook

6.1. Market Size & Forecast
- 6.1.1. By Value
6.2. Market Share & Forecast
- 6.2.1. By Indication
- 6.2.2. By Drug
- 6.2.3. By Route of Administration
- 6.2.4. By End User
- 6.2.5. By Country
6.3. North America: Country Analysis
- 6.3.1. United States Anticancer Drug Market Outlook
  - 6.3.1.1. Market Size & Forecast
    - 6.3.1.1.1. By Value
  - 6.3.1.2. Market Share & Forecast
    - 6.3.1.2.1. By Indication
    - 6.3.1.2.2. By Drug
    - 6.3.1.2.3. By Route of Administration
    - 6.3.1.2.4. By End User
- 6.3.2. Canada Anticancer Drug Market Outlook
  - 6.3.2.1. Market Size & Forecast
    - 6.3.2.1.1. By Value
  - 6.3.2.2. Market Share & Forecast
    - 6.3.2.2.1. By Indication
    - 6.3.2.2.2. By Drug
    - 6.3.2.2.3. By Route of Administration
    - 6.3.2.2.4. By End User
- 6.3.3. Mexico Anticancer Drug Market Outlook
  - 6.3.3.1. Market Size & Forecast
    - 6.3.3.1.1. By Value
  - 6.3.3.2. Market Share & Forecast
    - 6.3.3.2.1. By Indication
    - 6.3.3.2.2. By Drug
    - 6.3.3.2.3. By Route of Administration
    - 6.3.3.2.4. By End User

7. Europe Anticancer Drug Market Outlook

7.1. Market Size & Forecast
- 7.1.1. By Value
7.2. Market Share & Forecast
- 7.2.1. By Indication
- 7.2.2. By Drug
- 7.2.3. By Route of Administration
- 7.2.4. By End User
- 7.2.5. By Country
7.3. Europe: Country Analysis
- 7.3.1. Germany Anticancer Drug Market Outlook
  - 7.3.1.1. Market Size & Forecast
    - 7.3.1.1.1. By Value
  - 7.3.1.2. Market Share & Forecast
    - 7.3.1.2.1. By Indication
    - 7.3.1.2.2. By Drug
    - 7.3.1.2.3. By Route of Administration
    - 7.3.1.2.4. By End User
- 7.3.2. France Anticancer Drug Market Outlook
  - 7.3.2.1. Market Size & Forecast
    - 7.3.2.1.1. By Value
  - 7.3.2.2. Market Share & Forecast
    - 7.3.2.2.1. By Indication
    - 7.3.2.2.2. By Drug
    - 7.3.2.2.3. By Route of Administration
    - 7.3.2.2.4. By End User
- 7.3.3. United Kingdom Anticancer Drug Market Outlook
  - 7.3.3.1. Market Size & Forecast
    - 7.3.3.1.1. By Value
  - 7.3.3.2. Market Share & Forecast
    - 7.3.3.2.1. By Indication
    - 7.3.3.2.2. By Drug
    - 7.3.3.2.3. By Route of Administration
    - 7.3.3.2.4. By End User
- 7.3.4. Italy Anticancer Drug Market Outlook
  - 7.3.4.1. Market Size & Forecast
    - 7.3.4.1.1. By Value
  - 7.3.4.2. Market Share & Forecast
    - 7.3.4.2.1. By Indication
    - 7.3.4.2.2. By Drug
    - 7.3.4.2.3. By Route of Administration
    - 7.3.4.2.4. By End User
- 7.3.5. Spain Anticancer Drug Market Outlook
  - 7.3.5.1. Market Size & Forecast
    - 7.3.5.1.1. By Value
  - 7.3.5.2. Market Share & Forecast
    - 7.3.5.2.1. By Indication
    - 7.3.5.2.2. By Drug
    - 7.3.5.2.3. By Route of Administration
    - 7.3.5.2.4. By End User

8. Asia Pacific Anticancer Drug Market Outlook

8.1. Market Size & Forecast
- 8.1.1. By Value
8.2. Market Share & Forecast
- 8.2.1. By Indication
- 8.2.2. By Drug
- 8.2.3. By Route of Administration
- 8.2.4. By End User
- 8.2.5. By Country
8.3. Asia Pacific: Country Analysis
- 8.3.1. China Anticancer Drug Market Outlook
  - 8.3.1.1. Market Size & Forecast
    - 8.3.1.1.1. By Value
  - 8.3.1.2. Market Share & Forecast
    - 8.3.1.2.1. By Indication
    - 8.3.1.2.2. By Drug
    - 8.3.1.2.3. By Route of Administration
    - 8.3.1.2.4. By End User
- 8.3.2. India Anticancer Drug Market Outlook
  - 8.3.2.1. Market Size & Forecast
    - 8.3.2.1.1. By Value
  - 8.3.2.2. Market Share & Forecast
    - 8.3.2.2.1. By Indication
    - 8.3.2.2.2. By Drug
    - 8.3.2.2.3. By Route of Administration
    - 8.3.2.2.4. By End User
- 8.3.3. Japan Anticancer Drug Market Outlook
  - 8.3.3.1. Market Size & Forecast
    - 8.3.3.1.1. By Value
  - 8.3.3.2. Market Share & Forecast
    - 8.3.3.2.1. By Indication
    - 8.3.3.2.2. By Drug
    - 8.3.3.2.3. By Route of Administration
    - 8.3.3.2.4. By End User
- 8.3.4. South Korea Anticancer Drug Market Outlook
  - 8.3.4.1. Market Size & Forecast
    - 8.3.4.1.1. By Value
  - 8.3.4.2. Market Share & Forecast
    - 8.3.4.2.1. By Indication
    - 8.3.4.2.2. By Drug
    - 8.3.4.2.3. By Route of Administration
    - 8.3.4.2.4. By End User
- 8.3.5. Australia Anticancer Drug Market Outlook
  - 8.3.5.1. Market Size & Forecast
    - 8.3.5.1.1. By Value
  - 8.3.5.2. Market Share & Forecast
    - 8.3.5.2.1. By Indication
    - 8.3.5.2.2. By Drug
    - 8.3.5.2.3. By Route of Administration
    - 8.3.5.2.4. By End User

9. Middle East & Africa Anticancer Drug Market Outlook

9.1. Market Size & Forecast
- 9.1.1. By Value
9.2. Market Share & Forecast
- 9.2.1. By Indication
- 9.2.2. By Drug
- 9.2.3. By Route of Administration
- 9.2.4. By End User
- 9.2.5. By Country
9.3. Middle East & Africa: Country Analysis
- 9.3.1. Saudi Arabia Anticancer Drug Market Outlook
  - 9.3.1.1. Market Size & Forecast
    - 9.3.1.1.1. By Value
  - 9.3.1.2. Market Share & Forecast
    - 9.3.1.2.1. By Indication
    - 9.3.1.2.2. By Drug
    - 9.3.1.2.3. By Route of Administration
    - 9.3.1.2.4. By End User
- 9.3.2. UAE Anticancer Drug Market Outlook
  - 9.3.2.1. Market Size & Forecast
    - 9.3.2.1.1. By Value
  - 9.3.2.2. Market Share & Forecast
    - 9.3.2.2.1. By Indication
    - 9.3.2.2.2. By Drug
    - 9.3.2.2.3. By Route of Administration
    - 9.3.2.2.4. By End User
- 9.3.3. South Africa Anticancer Drug Market Outlook
  - 9.3.3.1. Market Size & Forecast
    - 9.3.3.1.1. By Value
  - 9.3.3.2. Market Share & Forecast
    - 9.3.3.2.1. By Indication
    - 9.3.3.2.2. By Drug
    - 9.3.3.2.3. By Route of Administration
    - 9.3.3.2.4. By End User

10. South America Anticancer Drug Market Outlook

10.1. Market Size & Forecast
- 10.1.1. By Value
10.2. Market Share & Forecast
- 10.2.1. By Indication
- 10.2.2. By Drug
- 10.2.3. By Route of Administration
- 10.2.4. By End User
- 10.2.5. By Country
10.3. South America: Country Analysis
- 10.3.1. Brazil Anticancer Drug Market Outlook
  - 10.3.1.1. Market Size & Forecast
    - 10.3.1.1.1. By Value
  - 10.3.1.2. Market Share & Forecast
    - 10.3.1.2.1. By Indication
    - 10.3.1.2.2. By Drug
    - 10.3.1.2.3. By Route of Administration
    - 10.3.1.2.4. By End User
- 10.3.2. Colombia Anticancer Drug Market Outlook
  - 10.3.2.1. Market Size & Forecast
    - 10.3.2.1.1. By Value
  - 10.3.2.2. Market Share & Forecast
    - 10.3.2.2.1. By Indication
    - 10.3.2.2.2. By Drug
    - 10.3.2.2.3. By Route of Administration
    - 10.3.2.2.4. By End User
- 10.3.3. Argentina Anticancer Drug Market Outlook
  - 10.3.3.1. Market Size & Forecast
    - 10.3.3.1.1. By Value
  - 10.3.3.2. Market Share & Forecast
    - 10.3.3.2.1. By Indication
    - 10.3.3.2.2. By Drug
    - 10.3.3.2.3. By Route of Administration
    - 10.3.3.2.4. By End User

11. Market Dynamics

11.1. Drivers
11.2. Challenges

12. Market Trends & Developments

12.1. Merger & Acquisition (If Any)
12.2. Product Launches (If Any)
12.3. Recent Developments

13. Global Anticancer Drug Market: SWOT Analysis

14. Porter's Five Forces Analysis

14.1. Competition in the Industry
14.2. Potential of New Entrants
14.3. Power of Suppliers
14.4. Power of Customers
14.5. Threat of Substitute Products

15. Competitive Landscape

15.1. F. Hoffmann-La Roche Ltd.
- 15.1.1. Business Overview
- 15.1.2. Products & Services
- 15.1.3. Recent Developments
- 15.1.4. Key Personnel
- 15.1.5. SWOT Analysis
15.2. Genentech, Inc.
15.3. Novartis AG
15.4. Pfizer Inc.
15.5. Bristol-Myers Squibb Company
15.6. GlaxoSmithKline plc.
15.7. Eli Lilly and Company (India) Pvt. Ltd.
15.8. AstraZeneca plc
15.9. Sanofi S.A.
15.10. Bayer AG